Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02303041 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
A Phase 2 study, sponsored by Anne Chang.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02303041 is a Phase 2 study that was terminated before completion, run by Anne Chang. The registered enrollment target is 10 participants.
The verdict
NCT02303041, a Phase 2 study, was terminated before completion, sponsored by Anne Chang.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Sonidegib
- DRUG Buparlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02303041
The ClinicalTrials.gov registry entry for NCT02303041 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anne Chang, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sonidegib is the first listed.
NCT02303041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02303041 about?
NCT02303041 is a clinical study titled "Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma". This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02303041?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-02. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02303041?
The interventions under investigation include: Sonidegib (DRUG), Buparlisib (DRUG).
Who is sponsoring clinical trial NCT02303041?
This trial is sponsored by Anne Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.